The data from the CDC's National Immunization Survey estimates that 37.6% of Americans ages 65 and older had gotten a shot of ...
BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...
TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and standalone ...
Health agencies, counties and state officials have been resisting efforts to provide booster jabs to Americans this fall.